Skip to main content

3 Result(s)

within Medicine & Public Health Remove this filter Emmanuel Mitry Remove this filter Article Remove this filter

and
Your search also matched 6 preview-only Content is preview-only when you or your institution have not yet subscribed to it.

By making our abstracts and previews universally accessible we help you purchase only the content that is relevant to you. results, e.g.

No evidence of somatic FGFR3 mutation in various types of carcinoma

Include preview-only content

  1. Article

    Biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin (TEF) as first-line treatment for advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: safety and efficacy in a multicenter cohort

    Docetaxel–cisplatin-5-FU chemotherapy is superior to 5-FU-cisplatin in terms of response rate and survival in advanced gastric cancer (AGC), but is more toxic. Oxaliplatin is better tolerated than cisplatin, w...

    Simon Pernot, Emmanuel Mitry, Emmanuelle Samalin, Laetitia Dahan… in Gastric Cancer (2014)

    Download PDF (221 KB) View Article

  2. Article

    Erratum to: Chemoembolization of Neuroendocrine Liver Metastases Using Streptozocin and Tris-acryl Microspheres: Embozar (EMBOsphere + ZAnosaR) Study

    Jean-Pierre Pelage, Audrey Fohlen… in CardioVascular and Interventional Radiology (2017)

    Download PDF (288 KB) View Article

  3. Article

    Open Access

    Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial

    Moxetumomab pasudotox is a recombinant CD22-targeting immunotoxin. Here, we present the long-term follow-up analysis of the pivotal, multicenter, open-label trial (NCT01829711) of moxetumomab pasudotox in pati...

    Robert J. Kreitman, Claire Dearden, Pier Luigi Zinzani… in Journal of Hematology & Oncology (2021)

    Download PDF (1076 KB) View Article